TITLE

Pneumocystis jiroveci Genotypes and Primary Infection

AUTHOR(S)
Totet, Anne; Respaldiza, Nieves; Pautard, Jean-Claude; Raccurt, Christian; Nevez, Gilles
PUB. DATE
May 2003
SOURCE
Clinical Infectious Diseases;5/15/2003, Vol. 36 Issue 10, p1340
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This study describes the molecular typing of Pneumocystis jiroveci organisms from 5 nonpremature immunocompetent infants who developed a primary infection. Four P. jiroveci internal transcribed spacer (ITS) types were identified. All have been previously described in reports concerning im-munosuppressed adults with pneumocystosis. Present data suggest that identical types can be implicated either in first contact or in additional contacts between fungus and host and that both immunocompetent infants and immunocom-promised patients may be part of a common human reservoir for the fungus.
ACCESSION #
9768975

 

Related Articles

  • New Jersey mandates flu shot.  // Drug Topics;10/20/97, Vol. 141 Issue 20, p8 

    Reports that New Jersey has implemented the `Get the Flu Shot & the Pneu Shot,' program, which requires that nursing homes offer influenza and pneumococcal pneumonia immunizations to elderly residents. Concerns about a rise in upper respiratory infections.

  • Environmental Contribution to the Allergic Asthma Epidemic. Kheradmand, Farrah; Rishi, Kirtee; Corry, David B. // Environmental Health Perspectives Supplements;Aug2002 Supplement 4, Vol. 110, p553 

    Current data overwhelmingly document the existence of a worldwide asthma epidemic, although individual studies remain controversial. The epidemic is thought to involve primarily persons with allergic asthma, and many diverse theories, based on an immunopathologic understanding of disease, have...

  • NEWSLINE: Prevnar 13 for Adults ≥50yrs.  // Monthly Prescribing Reference;Jan2012, Vol. 28 Issue 1, pA-6 

    The article reports that drug Prevnar 13, has been approved as a single dose for active immunization for the prevention of pneumonia and invasive disease, for adults who are of 50 years of age and older.

  • Immunization against pneumococcal infection.  // American Family Physician;11/15/1994, Vol. 50 Issue 7, p1513 

    Focuses on streptococcus pneumoniae, a major cause of morbidity and mortality in the United States. Groups at increased risk for pneumococcal disease; Basics of pneumococcal immunization; Poor implementation of immunization recommendations in the United States.

  • Correction: Tc17 Cells Mediate Vaccine Immunity against Lethal Fungal Pneumonia in Immune Deficient Hosts Lacking CD4+ T Cells.  // PLoS Pathogens;Apr2014, Vol. 10 Issue 4, p1 

    A correction to the article " Tc17 Cells Mediate Vaccine Immunity Against Lethal Fungal Pneumonia in Immune Deficient Hosts Lacking CD4>+ T Cells" that was published in a previous issue is presented.

  • Immune Response to Capsular Polysaccharide and Surface Proteins of Streptococcus pneumoniae in Patients with Invasive Pneumococcal Disease. Zysk, Gregor; Bethe, Gesina; Nau, Roland; Koch, Daniela; von Bassewitz, Valeska C.D.H. Gräfin; Heinz, Hans-Peter; Reinert, Ralf R. // Journal of Infectious Diseases;1/15/2003, Vol. 187 Issue 2, p330 

    The immune response to pneumococcal capsular polysaccharides (CPSs) and to the pneumococcal surface proteins cell wall-associated serine proteinase A (PrtA), pneumococcal surface protein A (PspA), and Streptococcus pneumoniae pullulanase A was evaluated in 45 patients with invasive pneumococcal...

  • Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. Earnshaw, Stephanie R.; McDade, Cheryl L.; Zanotti, Giovanni; Farkouh, Raymond A.; Strutton, David // BMC Infectious Diseases;2012, Vol. 12 Issue 1, p101 

    Background: Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 10-valent pneumococcal conjugate vaccine (PCV10) are two recently approved vaccines for the active immunization against Streptococcus pneumoniae causing invasive pneumococcal disease in infants and children. PCV13 offers...

  • Community acquired pneumonia: common causes, treatment and resistance. Banning, Maggie // Nurse Prescribing;Oct2005, Vol. 3 Issue 5, p195 

    In the UK, older people are particularly prone to developing community acquired pneumonia. The most common pathogen is the bacterium Streptococcus pneumoniae. In the environment, S. pneumoniae is a robust microbe that can adapt and survive in hostile conditions and in the human body. Antibiotic...

  • Protective Contributions against Invasive Streptococcus pneumoniae Pneumonia of Antibody and Th17-Cell Responses to Nasopharyngeal Colonisation. Cohen, Jonathan M.; Khandavilli, Suneeta; Camberlein, Emilie; Hyams, Catherine; Baxendale, Helen E.; Brown, Jeremy S. // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    The nasopharyngeal commensal bacteria Streptococcus pneumoniae is also a frequent cause of serious infections. Nasopharyngeal colonisation with S. pneumoniae inhibits subsequent re-colonisation by inducing Th17-cell adaptive responses, whereas vaccination prevents invasive infections by inducing...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics